Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 2/20 | 0.37 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.35 |
| ▸ | CPB1 | P15086 | 1/20 | 0.35 |
| ▸ | PREP | P48147 | 2/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | CTSL | P07711 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL483016 | 1.00 | NAAA (0.37) | NAAAKCNQ2CPB1PREPADORA2A | |
| SCHEMBL483165 | 0.87 | NAAA (0.37) | NAAAKCNQ2CPB1PREPADORA2A | |
| SCHEMBL483166 | 0.87 | NAAA (0.37) | NAAAKCNQ2CPB1PREPADORA2A | |
| SCHEMBL483039 | 0.82 | BRD4 (0.36) | NAAACPB1 | |
| SCHEMBL483012 | 0.79 | CTSL (0.37) | NAAAKCNQ2CTSKALDH1A1CTSL | |
| SCHEMBL482605 | 0.73 | NAAA (0.41) | NAAAKCNQ2CPB1ALDH1A1GAA | |
| SCHEMBL17758594 | 0.72 | NAAA (0.59) | NAAACTSKALDH1A1GAACTSL | |
| SCHEMBL483164 | 0.72 | MEN1 (0.38) | NAAAKCNQ2PREPALDH1A1CTSL | |
| SCHEMBL6279081 | 0.72 | KCNQ2 (0.48) | NAAAKCNQ2CPB1ALDH1A1GAA | |
| SCHEMBL4118291 | 0.72 | KCNQ2 (0.48) | NAAAKCNQ2CPB1ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8604030-B2 | Fused piperidine compound and pharmaceutical containing same | KOWA COMPANY, LTD. (JP) | 2013-12-10 | — | — | US | disclosed |
| US-20120108581-A1 | FUSED PIPERIDINE COMPOUND AND PHARMACEUTICAL CONTAINING SAME | KOWA COMPANY, LTD (JP) | 2012-05-03 | — | — | US | disclosed |
| EP-2412710-A1 | FUSED PIPERIDINE COMPOUND AND PHARMACEUTICAL AGENT COMPRISING SAME | Kowa Company, Ltd. (JP) | 2012-02-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108581-A1 | FUSED PIPERIDINE COMPOUND AND PHARMACEUTICAL CONTAINING SAME | EPOR, JAK2, HBZ | NAAA 4450/4885KCNQ2 1972/4885CPB1 3218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.